White Collar Worker...
Health Care: Drugs
Spectrum Pharmaceuticals Inc (SPPI: NASDAQ)
$14.21 -0.14 | -0.98%
02/06/12 - 04:00 PM ET
1.45M / 1.57M
Vol / Avg. Vol:14.27 / 14.35
Open / Prev. Close:14.15 - 14.49
Today's Range:6.18 - 16.00
52 Wk Range:-2.87%
Performance YTD:TheStreet Rating:
Portfolios with SPPI
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserStock/ETF
- ContributorHeavily Shorted Market Lead...
- ContributorHot Biotech Trades for Seco...
- Userone for the wife
- Contributor5 Bargain Biotech Stocks
- Userabdude
- Userdec28/10
- ContributorBarron's Insider Purchases ...
- UserMacpicks
Latest SPPI Headlines from TheStreet
- Spectrum Reaches New 52-Week High (SPPI) 01.09.12 | 01:01 pm
- Friday's Top 10 Articles, Videos 01.06.12 | 01:01 pm
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- 8 Stocks Rising on Unusual Volume 12.19.11 | 12:12 pm
- Spectrum Stock Hits New 52-Week High (SPPI) 12.19.11 | 10:12 am
- The Best Biotech CEO of 2011 Is ... 12.14.11 | 06:12 am
- Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- Best Biotech CEO of 2011 -- Vote Here 12.06.11 | 06:12 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Spectrum Stock Hits New 52-Week High (SPPI) 11.30.11 | 10:11 am
Press Releases for SPPI
- Spectrum Pharmaceuticals In-Licenses A Novel, Long-Acting GCSF Drug In U.S. Clinical Trials From Hanmi Pharmaceuticals - Business Wire 01.31.12 | 07:01 am
- Spectrum Pharmaceuticals Strengthens Commercial Operations - Business Wire 01.27.12 | 07:01 am
- Spectrum Pharmaceuticals To Acquire Worldwide Rights To Market ZEVALIN® - Business Wire 01.25.12 | 10:01 am
- ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective In Aggressive Lymphoma; Randomized Study Published In “CANCER”, The Journal Of The American Cancer Society - Business Wire 01.23.12 | 07:01 am
- Spectrum Pharmaceuticals To Present At The J. P. Morgan Healthcare Conference - Business Wire 01.04.12 | 07:01 am
- Impressive ZEVALIN® Data Highlighted At 53rd Annual Meeting Of The American Society Of Hematology; Spectrum To Increase Clinical Efforts To Expand ZEVALIN Indications - Business Wire 12.12.11 | 07:12 am
- Multifaceted Repositioning Campaign For ZEVALIN® Unveiled At ASH 2011, Following Recent FDA Approval To Remove Bioscan Requirement - Business Wire 12.12.11 | 07:12 am
- Spectrum Pharmaceuticals Affirms Strong Patent Protection For FUSILEV® (levoleucovorin) Through December 31, 2019 - Business Wire 12.09.11 | 02:12 pm
- Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations At The 53rd Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 10-13, 2011 - Business Wire 12.09.11 | 07:12 am
- Spectrum Pharmaceuticals To Present At The Oppenheimer & Co. 22nd Annual Healthcare Conference - Business Wire 12.07.11 | 07:12 am
Partner Headlines for SPPI
- Spectrum's Fusilev Sales Will Suffer As Leucovorin Shortage Is Eliminated - Seeking Alpha 12.11.11 | 07:12 am
- Benzinga's M&A Chatter for Friday December 9, 2011 - Benzinga 12.09.11 | 05:12 pm
- Rodman & Renshaw Maintains Market Outperform Rating on Spectrum Pharma - Benzinga 12.09.11 | 01:12 pm
- Stocks To Watch As Volatility Abounds In Europe - Seeking Alpha 11.16.11 | 08:11 am
- Spectrum Pharmaceuticals, Inc. - Momentum - Zacks 11.09.11 | 01:11 am
- Spectrum Pharmaceuticals Trumps The Shorts - Seeking Alpha 11.02.11 | 09:11 am
- 10 Stocks To Watch This Week - Seeking Alpha 10.16.11 | 09:10 am
- Add Questcor To Your Diversified High-Growth Biotech Portfolio - Seeking Alpha 08.28.11 | 06:08 am
- Spectrum Pharmaceuticals: A Great Biotech Company For Around $8 - Seeking Alpha 08.26.11 | 05:08 am
- Don't Miss Out on Upcoming Boom in Biosimilars - Seeking Alpha 07.22.11 | 05:07 pm
